Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR3 amp||Advanced Solid Tumor||predicted - sensitive||FGFR Inhibitor (Pan)||Ponatinib||Preclinical||Actionable||In a preclinical study, Iclusig (ponatinib) inhibited growth of several tumor cell lines with FGFR alterations in culture (Cancer Res April 15, 2011 71:3560).||detail...|
|FGFR3 amp||lung non-small cell carcinoma||sensitive||FGFR Inhibitor (Pan)||PRN1371||Preclinical - Pdx||Actionable||In a preclinical study, PRN1371 treatment resulted in 28.2% tumor growth inhibition in patient-derived xenograft models of FGFR3-amplified non-small cell lung cancer (PMID: 28978721).||28978721|
|FGFR3 amp||urinary system cancer||sensitive||FGFR3 Inhibitor||AZD4547||Preclinical - Cell culture||Actionable||In a preclinical study, AZD4547 decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245).||27401245|
|FGFR3 amp||urinary system cancer||sensitive||FGFR Inhibitor (Pan)||Infigratinib||Preclinical - Cell culture||Actionable||In a preclinical study, Truseltiq (infigratinib) decreased Myc expression, induced cell cycle arrest, and inhibited growth of a urinary tract cancer cell line harboring FGFR3 amplification in culture (PMID: 27401245).||27401245|
|FGFR3 amp||Advanced Solid Tumor||predicted - sensitive||FGFR3 Inhibitor||Debio 1347||Phase I||Actionable||In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297).||30745300|
|FGFR3 amp||urinary bladder cancer||sensitive||FGFR3 Inhibitor||3D185||Preclinical - Cell culture||Actionable||In a preclinical study, 3D185 inhibited proliferation of a bladder cancer cell line harboring FGFR3 amplification in culture (PMID: 31438996).||31438996|